GI Dynamics announces new findings that show elimination of and reduced reliance on insulin by patients treated with EndoBarrier Therapy

16-05-2014 Business Wire HealthComments (0)

BiologyDiabetesGI DynamicsHealth Medical PharmaHospitality RecreationMedicinePharmaceuticalUSA

GI Dynamics (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, today announced new findings that show that EndoBarrier Therapy enabled a rapid reduction in, and elimination of, insulin therapy by patients with type 2 diabetes and obesity. These findings from a retrospective analysis of 100 patients in Australia were presented at the American Association for Clinical Endocrinology 23rd Annual Meeting

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top